International Journal of Infertility & Fetal Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  15 (2024)
Volume  14 (2023)
Volume  13 (2022)
Volume  12 (2021)
Volume  11 (2020)
Volume  10 (2019)
Volume  9 (2018)
Volume  8 (2017)
Volume  7 (2016)
Volume  6 (2015)
Volume  5 (2014)
Volume  4 (2013)
Volume  3 (2012)
Volume  2 (2011)
Volume  1 (2010)
Related articles

VOLUME 8 , ISSUE 2 ( May-August, 2017 ) > List of Articles

RESEARCH ARTICLE

Efficacy of Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome: A Randomized, Double-blind and Placebo-controlled Trial

Swati Singh, Sankalp Singh, Ambujakshy K Raman, Sujatha Ramakrishnan, C Mohamed Ashraf

Citation Information : Singh S, Singh S, Raman AK, Ramakrishnan S, Ashraf CM. Efficacy of Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome: A Randomized, Double-blind and Placebo-controlled Trial. Int J Infertil Fetal Med 2017; 8 (2):54-60.

DOI: 10.5005/jp-journals-10016-1149

License: CC BY-NC 4.0

Published Online: 01-08-2013

Copyright Statement:  Copyright © 2017; The Author(s).


Abstract

Introduction

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication that arises due to assisted reproductive technologies (ARTs) during infertility treatment. Recently, the use of selective dopamine receptor agonists on D2 receptors (e.g., cabergoline) has been suggested in the prevention of OHSS. The aim of this study was to evaluate the effect of cabergoline in the prevention of OHSS in high-risk patients undergoing ART.

Materials and methods

This was a randomized, double-blind, parallel group (cabergoline group and placebo) study. A total of 110 women undergoing in vitro fertilization (IVF)–intracytoplasmic sperm injection procedure using a long agonist protocol with high risk for OHSS were recruited for the study on the day of final trigger. All the patients were followed up every 48 hours for 10 days from the day of the final trigger and clinically assessed with ultrasound and blood tests. The size of ovaries and fluid collection in the pouch of Douglas (POD) was measured with ultrasound. A sample size of 92 subjects was calculated for the study to be powered at 80%. Assuming a drop-out rate of 10%, 110 subjects were enrolled for the study.

Results

There was no significant difference observed in the size of right and left ovary, POD fluid volume, total leukocyte count (TLC), and serum estradiol level (E2 level) between both the groups from day 0 to day 8, except packed cell volume. No significant difference was observed in the incidence rate of moderate OHSS between both groups (p = 0.728). The differences in clinical pregnancy rate, implantation rate, and live birth rate were also insignificant.

Conclusion

Cabergoline does not reduce the incidence of moderate OHSS when compared with placebo. Large, well-designed studies are needed to evaluate the effectiveness of cabergoline when used for the prevention of OHSS.

How to cite this article

Singh S, Singh S, Raman AK, Ramakrishnan S, Ashraf CM. Efficacy of Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome: A Randomized, Double-blind and Placebo-controlled Trial. Int J Infertil Fetal Med 2017;8(2):54-60

HTML PDF Share
  1. Ovarian hyperstimulation syndrome. Obstet Gynaecol 2013 Jan;15(1):31-35.
  2. High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil Steril 2009 Sep;92(3):1168.e1-1168.e4.
  3. Cabergoline as a preventive measure against ovarian hyper-stimulation syndrome in assistive reproductive programs. Int J Sci Res Innov Tech 2015 Feb;2(2):57-62.
  4. Pharmacologic interventions in preventing ovarian hyperstimulation syndrome: a systematic review and network meta-analysis. Sci Rep 2016 Jan;6:19093.
  5. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Hum Fertil (Camb) 2007 Jun;10(2):75-85.
  6. Ovarian hyperstimulation syndrome. J Hum Reprod Sci 2011 May-Aug;4(2):70-75.
  7. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008 Jul-Aug;14(4):321-333.
  8. Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertil Steril 2002 Sep;78(3):529-533.
  9. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril 2010 May;93(7):2281-2284.
  10. Intra‐venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011 Feb;2:CD001302.
  11. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol 2001 Jun;96(2):187-192.
  12. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertil Steril 2011 Jul;96(1):53-57.
  13. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2012 Feb;2:CD008605.
  14. VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: current status. Med J Armed Forces India 2014 Jan;70(1):58-63.
  15. The effectiveness of cabergoline for the prevention of ovarian hyperstimulation syndrome. Iran J Med Sci 2011 Sep;36(3):207-212.
  16. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007 Dec;22(12):3210-3214.
  17. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2014 Mar;101(3):664-675.
  18. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010 Mar;340:c332.
  19. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006 Jan;85(1):112-120.
  20. Prevention of OHSS: current strategies and new insights. Middle East Fertil Soc J 2010 Oct;15(4):223-230.
  21. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008 Oct;17(6):751-755.
  22. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002 Nov;39(4-5):225-237.
  23. Prevention of ovarian hyperstimulation syndrome: a review. Obstet Gynecol Int J 2015 Apr;2015:1-10.
  24. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002 Nov;143(11):4339-4348.
  25. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001 May;7(5):569-574.
  26. Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial. Reprod Biomed Online 2013 Jun;26(6):562-568.
  27. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006 Apr;125(2):152-164.
  28. Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna J Med 2015 Oct-Dec;5(4):123-127.
  29. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. Eur J Obstet Gynecol Reprod Biol 2012 Sep;165(2):254-258.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.